AU2015257594A1 - Modulators of androgen synthesis - Google Patents

Modulators of androgen synthesis Download PDF

Info

Publication number
AU2015257594A1
AU2015257594A1 AU2015257594A AU2015257594A AU2015257594A1 AU 2015257594 A1 AU2015257594 A1 AU 2015257594A1 AU 2015257594 A AU2015257594 A AU 2015257594A AU 2015257594 A AU2015257594 A AU 2015257594A AU 2015257594 A1 AU2015257594 A1 AU 2015257594A1
Authority
AU
Australia
Prior art keywords
day
acid
conjugated
fatty acid
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015257594A
Other languages
English (en)
Inventor
Suzanne Jane Dilly
Gregory Alan Stoloff
Paul Christopher Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tangent Reprofiling Ltd
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of AU2015257594A1 publication Critical patent/AU2015257594A1/en
Priority to AU2018203135A priority Critical patent/AU2018203135A1/en
Priority to AU2019279922A priority patent/AU2019279922A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2015257594A 2014-05-09 2015-05-11 Modulators of androgen synthesis Abandoned AU2015257594A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018203135A AU2018203135A1 (en) 2014-05-09 2018-05-07 Modulators of androgen synthesis
AU2019279922A AU2019279922A1 (en) 2014-05-09 2019-12-09 Modulators of androgen synthesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990800P 2014-05-09 2014-05-09
US61/990,800 2014-05-09
PCT/EP2015/060388 WO2015169971A1 (en) 2014-05-09 2015-05-11 Modulators of androgen synthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203135A Division AU2018203135A1 (en) 2014-05-09 2018-05-07 Modulators of androgen synthesis

Publications (1)

Publication Number Publication Date
AU2015257594A1 true AU2015257594A1 (en) 2016-11-24

Family

ID=53269444

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015257594A Abandoned AU2015257594A1 (en) 2014-05-09 2015-05-11 Modulators of androgen synthesis
AU2018203135A Abandoned AU2018203135A1 (en) 2014-05-09 2018-05-07 Modulators of androgen synthesis
AU2019279922A Abandoned AU2019279922A1 (en) 2014-05-09 2019-12-09 Modulators of androgen synthesis

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018203135A Abandoned AU2018203135A1 (en) 2014-05-09 2018-05-07 Modulators of androgen synthesis
AU2019279922A Abandoned AU2019279922A1 (en) 2014-05-09 2019-12-09 Modulators of androgen synthesis

Country Status (8)

Country Link
EP (1) EP3139923B1 (enExample)
JP (1) JP6730194B2 (enExample)
CN (1) CN106456644B (enExample)
AU (3) AU2015257594A1 (enExample)
CA (1) CA2950800C (enExample)
ES (1) ES2970762T3 (enExample)
NZ (1) NZ726050A (enExample)
WO (1) WO2015169971A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211868A1 (en) 2012-09-26 2016-06-03 Tangent Reprofiling Limited Modulators of androgen synthesis
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
JP2020516283A (ja) 2017-04-11 2020-06-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN112020556A (zh) 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法
US11957687B2 (en) 2019-07-02 2024-04-16 Regeneron Pharmaceuticals, Inc. Modulators of HSD17B13 and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319950B1 (en) * 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
AU2002231190B2 (en) * 2000-12-23 2005-11-03 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
EP1626703A2 (en) * 2003-05-22 2006-02-22 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2012129673A1 (en) * 2011-03-25 2012-10-04 Universite Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
HK1211868A1 (en) * 2012-09-26 2016-06-03 Tangent Reprofiling Limited Modulators of androgen synthesis
US9375433B2 (en) * 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
JP2017514816A (ja) 2017-06-08
CN106456644B (zh) 2021-06-15
CN106456644A (zh) 2017-02-22
WO2015169971A1 (en) 2015-11-12
NZ726050A (en) 2018-04-27
CA2950800C (en) 2023-01-10
CA2950800A1 (en) 2015-11-12
AU2018203135A1 (en) 2018-05-24
AU2019279922A1 (en) 2020-01-16
JP6730194B2 (ja) 2020-07-29
ES2970762T3 (es) 2024-05-30
EP3139923A1 (en) 2017-03-15
EP3139923B1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
US10111877B2 (en) Modulators of androgen synthesis
AU2017221819B2 (en) Modulators of androgen synthesis
CA2950800C (en) Modulators of androgen synthesis
JP2017514816A5 (enExample)
US20050137185A1 (en) Combinations of drugs for the treatment of neoplasms
CN101217956A (zh) 用于治疗肿瘤的组合物和方法
TW200522947A (en) Combinations of drugs for the treatment of neoplasms
WO2004007676A2 (en) Combination therapy for the treatment of neoplasms
CN102448968A (zh) C-met蛋白激酶的取代的吡唑抑制剂
WO2004073631A2 (en) Combination therapy for the treatment of neoplasms

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted